CARBAPENEMS (IMIPENEM, MEROPENEM, DORIPENEM) IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA: CURRENT STATE OF THE PROBLEM
- Authors: Belousova Y.B.1, Zyryanov S.K.1, Shteynberg L.L.1, Belousov Y.B1, Zyryanov SK1, Shteynberg LL1
-
Affiliations:
- Issue: No 15 (2011)
- Pages: 16-23
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278977
- ID: 278977
Cite item
Full Text
Abstract
Keywords
About the authors
Yuriy Borisovich Belousova
Sergey Kensarinovich Zyryanov
Lyudmila L'vovna Shteynberg
Yu B Belousov
S K Zyryanov
L L Shteynberg
References
- Чучалин А.Г., Гельфанд Б.Р. Нозокомиальная пневмония у взрослых. Национальные рекомендации. 2009.
- American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005;171:388-416.
- Craven DE, Epidemiology of ventilator-associated pneumonia. Chest 2000;117(4).
- Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of Gram negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005;56(5): 893-98.
- Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemother 2005;51:227-33.
- Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother 2008;9(4):561-75.
- Masterton RG, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008.
- Marin H, Kollef MD. Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems. Respir Care 2004;49(12):1530-41.
- Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infection: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
- Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183-96.
- Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17(8):552-57.
- Arnold A, Brouse SD, William D. Pitcher and Ronald G. Hall II. Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind. J Intensive Care Med 2010;25:259.
- Яковлев С.В. Нозокомиальные инфекции, вызванные полирезистентными грамотрицательными микроорганизмами: как с ними бороться? // Consilium Medicum 2008. Т. 10. № 1.
- Sumita Y, Fukasawa M, Okuda T. Affi nities of SM-7338 for penicillin binding protein and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother 1990;34(3):484-6.
- Sumita Y, Fuksawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin binding protein and morphological changes. J Antibiot (Tokyo) 1990;43(3):314-20.
- Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against Gram negative bacteria with a permeability defect against staphylococci. J Antimicrob Chemother 1989;24:125-132.
- Rhomberg PR, Ronald NJ. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Disease 2008;65(4):414-26.
- Nordmann P, Picazo JJ, Mutters R, et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011.
- Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis. 2009;63(4):426-33.
- Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofl oxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38(3):547-57.
- Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients; a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47(11):3442-7.
- Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and pipercillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42(11):2966-72.
- Torres A, Bauer TT, Leon-Gill C, et al. Treatment of severe nosocomial pneumonia: a prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-39.
- Schmitt DV, Leitner E, Welte T, et al. Pipercillin/Tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind prospective multicentre study. Infection 2006;34:127-34.
- Joshi M, Metzler M, Mccarthy M, et al. Comparision of pipercillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006;100:1154-565.
- West M, Boulanger B, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;23(2):485-505.
- Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996;38:523-37.
- Garau J, Blanquer J, Cobo L, et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16:789-96.
- Alvarez-Lerma F, Santos FM, De Castro J, et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001;13(1):70-81.
- Santos SS, Machado FR, Kiffer CR, et al. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis2001;5(3):124-29.
- Berman SJ, Fogarty CM, Fabian T, et al. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004;16(4):362-71.
- Mouton YJ, Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36:145-56.
- Jaspers C, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment for serious infections in elderly patients. Antimicrob Agents Chemother 1998;42:1233-38.
- Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68(6):803-38.
- Seiger B, Berman SJ, Geckler R, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997;25(10):1663-70.
- Jones RN, Huynh HK, Biedenbach, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54:144-54.
- Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various â ?-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52:71.
- Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48(8):3136-40.
- Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect Dis 2005;11:974-84.
- Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot 2006;59(4):220-8.
- Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-92.
- Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006;55(3):241-3.
- Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24(7):2113-26.
- Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36(4):1089-96.
- Alvarez-Lerma F, Grau S, Ferrandez O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Design Develop Ther 2009:3 173-190.
- Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30(5):868-83.
- Solomkin J, Umeh O, Jiang J. Doripenem versus Imipenem for the treatment of complicated intraabdominal infections. In programm and abstracts of the 47thICAAC; American society for microbiology.
- Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30(4):717-33.
- Kongnakorn T, Mwamburi M, Merchant S, et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010;26(1):17-24.
- McGarry LJ, Merchant S, Nathwani D, et al. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Med Econ 2010;13(1):142.
Supplementary files
![](/img/style/loading.gif)